Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents.
about
Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.First- and second-line therapy for metastatic urothelial carcinoma of the bladderControversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.Adaptor protein CRK induces epithelial-mesenchymal transition and metastasis of bladder cancer cells through HGF/c-Met feedback loopHER2 as a target in invasive urothelial carcinoma.Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial CarcinomaTranscriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cellsEfficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis.Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells.Strategies to improve drug delivery in bladder cancer therapy.Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response.New agents for bladder cancer.The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers.
P2860
Q33662842-3E594EF1-7590-44D6-9E9C-A71CBD4339F9Q33670824-35F3EEE6-31FB-4346-8619-5D8FD202FAD3Q34541463-4722D165-66CD-44B5-938D-95733BAE893AQ35180823-2B7108AD-BEDE-4446-B143-82C5F5DAC446Q35754256-0591DF2F-0E05-49F8-A42F-B59A5E8AE73BQ35755382-564BB7AB-7CE3-4D0D-9C0C-60F23C2FC01FQ36236479-47703985-8844-42DF-8C74-5CE91DC2E5EFQ36305476-147B7C7F-31A6-478E-8A6D-EB01634E2DE1Q36650466-AD2E0EB7-584B-4871-96ED-A4CCCF8AE59CQ37283592-D443B167-5156-4650-98BA-F66267DE85BFQ37306965-B48B40AF-1352-4F38-89A0-077CFA927DC9Q37523962-2CF1B5B2-F2BE-4196-B6ED-920F55A2F285Q37797468-1AF82221-ADBC-4A5D-81B1-8D1035778851Q37799952-13E7D37E-5E15-4D4D-935B-C666869BC881Q38472348-B13BCBC3-A486-431F-B6C3-9FB4AA55256F
P2860
Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Optimizing therapeutic strateg ...... d the role of targeted agents.
@en
Optimizing therapeutic strateg ...... d the role of targeted agents.
@nl
type
label
Optimizing therapeutic strateg ...... d the role of targeted agents.
@en
Optimizing therapeutic strateg ...... d the role of targeted agents.
@nl
prefLabel
Optimizing therapeutic strateg ...... d the role of targeted agents.
@en
Optimizing therapeutic strateg ...... d the role of targeted agents.
@nl
P2093
P1476
Optimizing therapeutic strateg ...... d the role of targeted agents.
@en
P2093
P304
P356
10.1016/J.CRITREVONC.2008.06.002
P577
2008-07-21T00:00:00Z